FA
ABBV icon

Financial Advantage’s AbbVie ABBV Stock Holding History

Financial Advantage’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-1,200
Closed -$63K – 131
2013
Q4 		$63K Hold
1,200
– – 0.05% 59
2013
Q3 		$54K Hold
1,200
– – 0.05% 61
2013
Q2 		$50K Buy
+1,200
New +$52.5K 0.04% 64

Other funds holding ABBV

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Financial Advantage's ABBV Position: Q1 2014 in Review

Financial Advantage sold out of AbbVie (ABBV) in Q1 2014, closing a stake of 1,200 shares — an estimated $63K sold.

Financial Advantage first reported a position in ABBV in Q2 2013 and held it in 3 quarters. The position peaked at $63K in Q4 2013. 1,422 funds tracked by Wall St. Rank hold ABBV as of Q1 2014.

  • Financial Advantage reported no remaining AbbVie position as of Q1 2014 after selling out during the quarter.
  • Financial Advantage sold 1,200 AbbVie shares in Q1 2014, an estimated $63K.
  • Financial Advantage first reported a position in AbbVie in Q2 2013 and held it in 3 quarters.
  • Financial Advantage's AbbVie position peaked at $63K in Q4 2013.
  • 1,422 funds tracked by Wall St. Rank held AbbVie as of Q1 2014.

Based on Financial Advantage's 13F filing for Q1 2014, filed 9 May 2014.